Meta-Analysis Comparing Rosuvastatin and Atorvastatin in Reducing Concentration of C-Reactive Protein in Patients...

Area of Science:

• Cardiology
• Pharmacology
• Biochemistry

Background:

• Elevated C-reactive protein (CRP) is a marker of inflammation and cardiovascular risk.
• Statins are widely used to lower cholesterol and reduce cardiovascular events.
• Comparing the efficacy of different statins in reducing CRP is important for clinical practice.

Purpose of the Study:

• To compare the efficacy of rosuvastatin versus atorvastatin in reducing C-reactive protein (CRP) concentrations.
• To conduct a meta-analysis of randomized controlled trials (RCTs) evaluating rosuvastatin and atorvastatin for CRP reduction.

Main Methods:

• A systematic literature search was performed in PubMed, Ovid, and Elsevier databases up to June 2014.
• Included 13 randomized trials with a total of 3798 patients comparing rosuvastatin and atorvastatin.
• Meta-analysis and subgroup analyses were conducted to assess treatment efficacy and publication bias.

Main Results:

• Rosuvastatin significantly reduced CRP concentrations compared to atorvastatin (mean difference [MD] = -0.11, P < .0001).
• This benefit was consistent across different dosing ratios (1/1 and 1/2 rosuvastatin/atorvastatin).
• No significant publication bias was detected (I(2) = 6.9%, P = .377).

Conclusions:

• Rosuvastatin is more effective than atorvastatin in lowering CRP levels.
• The findings support the use of rosuvastatin for its potent anti-inflammatory effects, as indicated by CRP reduction.
• This meta-analysis provides robust evidence for rosuvastatin's superior CRP-lowering capacity.